· . . 🐒

Concern identified below: Name of Concern: ViroLogic, Inc. 270 East Grand Avenue South San Francisco, CA 94080 I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 C.F.R. \$121.3-18, reproduced in 37 C.F.R. \$1.9(d), for purposes of paying reduced fees under 35 U.S.C. \$41(a) and \$41(b), in that the number of employees of the concern, including those of its affiliates, does not exceed five hundred (500) persons. For purposes of this verified statement, the number of employees of the business concern is the average number, over the previous fiscal year, of the persons employed by the business concern on a full-time, part-time, or temporary basis during each pay period of the fiscal year, and concerns are affiliates of each other when, either directly or indirectly, one concern controls or has power to control the other, or a third party or parties controls on has power to control the other, or a third party or parties controls on has power to control both. I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention MEANS AND METHODS FOR MONITORING PROTEASE INHIBITOR ANTIRETROVIRAL THERAPY AND GUIDING THERAPEUTIC DECISIONS IN THE TREATMENT OF HIV/AIDS described in: X the specification filed herewith application serial no. issued If the rights held by the above identified small business concern are not exclusive each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 C.F.R. \$1.9(e)*. Name: N/A Address:		atent No.: Not	
SMALL ENTITY STATUS UNDER 37 C.F.R. §1.9(f) AND §1.27(d) - SMALL BUSINESS CONCERN I hereby declare that I am: the owner of the small business concern identified below. X an official of the small business concern empowered to act on behalf of the concern identified below: Name of Concern: ViroLogic, Inc. Address of Concern: 270 East Grand Avenue South San Francisco, CA 94080 I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 C.F.R. §121.3-18, reproduced in 37 C.F.R. §1.9(d), for purposes of paying reduced fees under 35 U.S.C. §41(a) and §41(b), in that the number of employees of the concern, including those of its affiliates, does not exceed five hundred (500) persons. For purposes of this verified statement, thumber of employees of the business concern is the average number, over the previous fiscal year, of the persons employed by the business concern on a full-time, part-time, or temporary basis during each pay period of the fiscal year, and concerns are affiliates of each other when, either directly or indirectly, one concern controls or has power to control both. I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention entitled makens AND METHODS FOR MONITORING PROTEASE INHIBITOR ANTIRETROVIRAL THERAPY AND GUIDING THERAPEUTIC DECISIONS IN THE TREATMENT OF HIV/AIDS described in: X the specification filed herewith application serial no. issued If the rights held by the above identified small business concern are not exclusive each individual, concern or organization having rights to the invention is lister below and no rights to the invention are held by any person, other than the invention, who could not qualify as an independent inventor under 37 C.F.R. §1.9(c)* any concern which could not qualify as a small business concern under 3 C.F.R. §1.9(e)*.	Filed or Iss Title of Inv	sued: <u>Her</u> vention or Patent	MEANS AND METHODS FOR MONITORING PROTEASE INHIBITO ANTIRETROVIRAL THERAPY AND GUIDING THERAPEUTIC
the owner of the small business concern identified below. X an official of the small business concern empowered to act on behalf of the concern identified below: Name of Concern: ViroLogic, Inc. 270 East Grand Avenue South San Francisco, CA 94080 I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 C.F.R. \$121.3-18, reproduced in 37 C.F.R. \$1.9(d), for purposes of paying reduced fees under 35 U.S.C. \$41(a) and \$41(b), in that the number of employees of the concern, including those of its affiliates, does not exceed five hundred (500) persons. For purposes of this verified statement, the number of employees of the business concern is the average number, over the previous fiscal year, of the persons employed by the business concern on a full-time, part-time, or temporary basis during each pay period of the fiscal year, and concerns are affiliates of each other when, either directly or indirectly, on concern controls or has power to control the other, or a third party or parties controls or has power to control both. I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention entitled MEANS AND METHODS FOR MONITORING PROTEASE INHIBITOR ANTIRETROVIRAL THERAPY AND GUIDING THERAPEUTIC DECISIONS IN THE TREATMENT OF HIV/AIDS described in: X the specification filed herewith application serial no. issued If the rights held by the above identified small business concern are not exclusive each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the invention who could not qualify as an independent inventor under 37 C.F.R. \$1.9(c)* any concern which could not qualify as a small business concern under 3 C.F.R. \$1.9(d)* or as a nonprofit organization under 37 C.F.R. \$1.9(e)*.		SMALL EN	D STATEMENT (DECLARATION) CLAIMING TITY STATUS UNDER 37 C.F.R. §1.9(f)
an official of the small business concern empowered to act on behalf of the concern identified below: Name of Concern: ViroLogic, Inc.	I hereby dec	clare that I am:	
concern identified below: Name of Concern: ViroLogic, Inc. 270 East Grand Avenue South San Francisco, CA 94080 I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 C.F.R. \$121.3-18, reproduced in 37 C.F.R. \$1.9(d), for purposes of paying reduced fees under 35 U.S.C. \$41(a) and \$41(b), in that the number of employees of the concern, including those of its affiliates, does not exceed five hundred (500) persons. For purposes of this verified statement, the number of employees of the business concern is the average number, over the previous fiscal year, of the persons employed by the business concern on a full-time, part-time, or temporary basis during each pay period of the fiscal year, and concerns are affiliates of each other when, either directly or indirectly, one concern controls or has power to control the other, or a third party or parties controls or has power to control the other, or a third party or parties controls or has power to control both. I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention MEANS AND METHODS FOR MONITORING PROTEASE INHIBITOR ANTIRETROVIRAL THERAPY AND GUIDDING THERAPEUTIC DECISIONS IN THE TREATMENT OF HIV/AIDS described in: X the specification filed herewith application serial no. issued If the rights held by the above identified small business concern are not exclusive each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 C.F.R. \$1.9(e)* any concern which could not qualify as a small business concern under 3 C.F.R. \$1.9(e)*.	ti	ne owner of the s	mall business concern identified below.
Address of Concern: 270 East Grand Avenue South San Francisco, CA 94080 I hereby declare that the above identified small business concern qualifies as small business concern as defined in 13 C.F.R. 5121.3-18, reproduced in 37 C.F.R. \$1.9(d), for purposes of paying reduced fees under 35 U.S.C. \$41(a) and \$41(b), in that the number of employees of the concern, including those of its affiliates, does not exceed five hundred (500) persons. For purposes of this verified statement, the number of employees of the business concern is the average number, over the previous fiscal year, of the persons employed by the business concern on a full-time, part-time, or temporary basis during each pay period of the fiscal year, and concern sare affiliates of each other when, either directly or indirectly, one concern controls or has power to control the other, or a third party or parties controls or has power to control the other, or a third party or parties with the small business concern identified above with regard to the invention entitled MEANS AND METHODS FOR MONITORING PROTEASE INHIBITOR ANTIRETROVIRAL THERAPY AND GUIDING THERAPEUTIC DECISIONS IN THE TREATMENT OF HIV/AIDS described in: X the specification filed herewith application serial no. issued If the rights held by the above identified small business concern are not exclusive each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 C.F.R. \$1.9(c)* any concern which could not qualify as small business concern under 3 C.F.R. \$1.9(c)*. NAME: N/A Address:			
South San Francisco, CA 94080 I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 C.F.R. §121.3-18, reproduced in 37 C.F.R. §1.9(d), for purposes of paying reduced fees under 35 U.S.C. §41(a) and §41(b), in that the number of employees of the concern, including those of its affiliates, does not exceed five hundred (500) persons. For purposes of this verified statement, the number of employees of the business concern is the average number, over the previous fiscal year, of the persons employed by the business concern on a full-time, part-time, or temporary basis during each pay period of the fiscal year, and concerns are affiliates of each other when, either directly or indirectly, one concern controls or has power to control the other, or a third party or parties controls or has power to control both. I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention entitled mEANS AND METHODS FOR MONITORING PROTEASE INHIBITOR ANTIRETROVIRAL THERAPY AND GUIDING THERAPEUTIC DECISIONS IN THE TREATMENT OF HIV/AIDS described in: X the specification filed herewith application serial no. issued If the rights held by the above identified small business concern are not exclusive each individual, concern or organization having rights to the invention is listerable below and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 C.F.R. §1.9(c)* any concern which could not qualify as a small business concern under 3 C.F.R. §1.9(c)*. NAME: N/A Address:	Name of Cond	cern:	ViroLogic, Inc.
I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 C.F.R. §121.3-18, reproduced in 37 C.F.R. §1.9(d), for purposes of paying reduced fees under 35 U.S.C. §41(a) and §41(b), in that the number of employees of the concern, including those of its affiliates, does not exceed five hundred (500) persons. For purposes of this verified statement, the number of employees of the business concern is the average number, over the previous fiscal year, of the persons employed by the business concern on a full-time, part-time, or temporary basis during each pay period of the fiscal year, and concerns are affiliates of each other when, either directly or indirectly, one concern controls or has power to control the other, or a third party or parties controls or has power to control both. I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention entitled MEANS AND METHODS FOR MONITORING PROTEASE INHIBITOR ANTIRETROVIRAL THERAPY AND GUIDING THERAPEUTIC DECISIONS IN THE TREATMENT OF HIV/AIDS described in: X the specification filed herewith application serial no. filed herewith application serial no. filed herewith application serial no. filed herewith application serial no issued If the rights held by the above identified small business concern are not exclusive each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 C.F.R. §1.9(c)*. Name: N/A Address:	Address of (Concern:	
MEANS AND METHODS FOR MONITORING PROTEASE INHIBITOR ANTIRETROVIRAL THERAPY AND GUIDING THERAPEUTIC DECISIONS IN THE TREATMENT OF HIV/AIDS described in: X the specification filed herewith application serial no. filed patent no. issued If the rights held by the above identified small business concern are not exclusive each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 C.F.R. \$1.9(c)* any concern which could not qualify as a small business concern under 3 C.F.R. \$1.9(d)* or as a nonprofit organization under 37 C.F.R. \$1.9(e)*. Name: N/A Address:	number of em	ive hundred (500) ployees of the bu	persons. For purposes of this verified statement, the siness concern is the average number, over the previous
application serial no	number of em fiscal year part-time, concerns are concern con- controls or I hereby dec	ive hundred (500) aployees of the but, of the persons or temporary base affiliates of trols or has powhas power to contain the contains that rights	persons. For purposes of this verified statement, the siness concern is the average number, over the previous employed by the business concern on a full-time, sis during each pay period of the fiscal year, and each other when, either directly or indirectly, one er to control the other, or a third party or parties atrol both. under contract or law have been conveyed to and remain
If the rights held by the above identified small business concern are not exclusive each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 C.F.R. \$1.9(c)* any concern which could not qualify as a small business concern under 3 C.F.R. \$1.9(d)* or as a nonprofit organization under 37 C.F.R. \$1.9(e)*. Name: N/A Address:	number of emfiscal year part-time, concerns are concern conficentials or I hereby decomplete with the smentitled MEANS AND MEGUIDING THE	ive hundred (500) aployees of the bu, of the persons or temporary base affiliates of trols or has pow has power to contain that rights all business corrected to the contest of the contes	persons. For purposes of this verified statement, the siness concern is the average number, over the previous semployed by the business concern on a full-time, sis during each pay period of the fiscal year, and each other when, either directly or indirectly, one er to control the other, or a third party or parties atrol both. under contract or law have been conveyed to and remain ocern identified above with regard to the invention ORING PROTEASE INHIBITOR ANTIRETROVIRAL THERAPY AND
	number of emfiscal year part-time, concerns are concern conficent controls or I hereby decwith the smentitled MEANS AND MEGUIDING THE described in	ive hundred (500) aployees of the but, of the persons or temporary base affiliates of trols or has power to contain the business contains all business content of the business	persons. For purposes of this verified statement, the siness concern is the average number, over the previous employed by the business concern on a full-time, sis during each pay period of the fiscal year, and each other when, either directly or indirectly, one er to control the other, or a third party or parties atrol both. under contract or law have been conveyed to and remain ocern identified above with regard to the invention ORING PROTEASE INHIBITOR ANTIRETROVIRAL THERAPY AND NS IN THE TREATMENT OF HIV/AIDS
Individual Small Business Concern Nonprofit Organization	number of em fiscal year part-time, concerns are concern cons controls or I hereby dec with the sm entitled MEANS AND M GUIDING THE described in X the sappling pater If the right each indivice below and inventor, wh any concern C.F.R. \$1.9	ive hundred (500) aployees of the but, of the persons or temporary base affiliates of trols or has power to contain the persons of the person	persons. For purposes of this verified statement, the siness concern is the average number, over the previous semployed by the business concern on a full-time, sis during each pay period of the fiscal year, and each other when, either directly or indirectly, one er to control the other, or a third party or parties atrol both. Under contract or law have been conveyed to and remain occarn identified above with regard to the invention of the invention is listed to the invention are held by any person, other than the five as an independent inventor under 37 C.F.R. \$1.9(c)*, not qualify as a small business concern under 37 concern

^aNOTE: Separate verified statements are required for each named person, concern, or organization having rights to the invention averring to their status as small entities. 37 C.F.R. §1.27.

Small Entity/Small Business Concern Page -2-

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. 37 C.F.R. \$1.28 (b) *.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Name of Person Signing: _ Title In Organization:	
Address:	
Signature:	
Signature: Date Of Signature:	

DECLARATION AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address, and cinzenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the inventon entitled:

MEAN AND METHODS FOR MONITORING PROTEASE INHIBITOR ANTIRETROVIRAL THERAPY AND GUIDING THERAPEUTIC DECISIONS IN THE TREATMENT OF HIV/AIDS

the specification (check one)				
	X is allached	d hereto.		
	was filed o	on	·	as
	Application Serial	No. Not Yet Kno	wn	
	and was amended			·
	·		(if ap	plicable)
including the claim	I have reviewed and unions. as amended by any am			
I hereby claim foreig 365(b) of any fore International Appl below. I have also International Applic	luty to disclose to the U.S. otentability as defined in gn priority benefits under lag napplication(s) for particular which designated identified below any fore the ton having a filing date	Tule 37. Code of Federo Tule 35. Unned States C tent or inventor's certific Tat least one country o tign application for pate	il Regulations, S Tode, Section 119 cate, or Section ther than the U nt or inventor's	Pection 1.56. P(a)-(d) or Section 365(a) of any PCT inited States, listed certificate, or PCT
In be material to per J hereby claim foreign 365(b) of any fore International Applibelow. I have also International Application is claimed:	oieniability as defined in gn priority benefits under f eign application(s) for pa ication which designated identified below any fore ration having a filing date	Tule 37. Code of Federo Tule 35. Unned States C tent or inventor's certific Tat least one country o tign application for pate	al Regulations, Sode, Section 119 case, or Section the Uniter than the Unit or inventor's est application f	Section 1.56. (a)-(d) or Section 365(a) of any PCT inited States, listed certificate, or PCT from which priority
I hereby claim foreign 365(b) of any foreign and Apple below. I have also international Application of the claimed: Prior Foreign Application	oieniobility as defined in gn priority benefits under fing napplication(s) for partication which designated identified below any fore ration having a filing date fication(s)	Tule 37. Code of Federo Tule 35. United States Citent or inventor's certiful I at least one country or ign application for pate I before that of the earlie	al Regulations, Social Regulations, Social Regulations, 119 and 119 an	Tection 1.56. P (a)-(d) or Section 365(a) of any PCT inited States, listed certificate, or PCT from which priority y Claimed
In be material to per J hereby claim foreign 365(b) of any fore International Applibelow. I have also International Application is claimed:	oieniability as defined in gn priority benefits under f eign application(s) for pa ication which designated identified below any fore ration having a filing date	Tule 37. Code of Federo Tule 35. Unned States C tent or inventor's certific Tat least one country o tign application for pate	al Regulations, Sode, Section 119 case, or Section the Uniter than the Unit or inventor's est application f	Section 1.56. (a)-(d) or Section 365(a) of any PCT inited States, listed certificate, or PCT from which priority
I hereby claim foreign 365(b) of any foreign and Apple below. I have also international Application of the claimed: Prior Foreign Application	oieniobility as defined in gn priority benefits under fing napplication(s) for partication which designated identified below any fore ration having a filing date fication(s)	Tule 37. Code of Federo Tule 35. United States Citent or inventor's certiful I at least one country or ign application for pate I before that of the earlie	al Regulations, Social Regulations, Social Regulations, 119 and 119 an	Tection 1.56. P (a)-(d) or Section 365(a) of any PCT inited States, listed certificate, or PCT from which priority y Claimed
I hereby claim foreign 365(b) of any foreign and Apple below. I have also international Application of the claimed: Prior Foreign Application	oieniobility as defined in gn priority benefits under fing napplication(s) for partication which designated identified below any fore ration having a filing date fication(s)	Tule 37. Code of Federo Tule 35. United States Citent or inventor's certiful I at least one country or ign application for pate I before that of the earlie	al Regulations, Social Regulations, Social Regulations, 119 and 119 an	Tection 1.56. P (a)-(d) or Section 365(a) of any PCT inited States, listed certificate, or PCT from which priority y Claimed
I hereby claim foreign 365(b) of any foreign and Apple below. I have also international Application of the claimed: Prior Foreign Application	oieniobility as defined in gn priority benefits under fing napplication(s) for partication which designated identified below any fore ration having a filing date fication(s)	Tule 37. Code of Federo Tule 35. United States Citent or inventor's certiful I at least one country or ign application for pate I before that of the earlie	al Regulations, Social Regulations, Social Regulations, 119 and 119 an	Tection 1.56. P (a)-(d) or Section 365(a) of any PCT inited States, listed certificate, or PCT from which priority y Claimed
I hereby claim foreign 365(b) of any foreign and Apple below. I have also international Application of the claimed: Prior Foreign Application	oieniobility as defined in gn priority benefits under fing napplication(s) for partication which designated identified below any fore ration having a filing date fication(s)	Tule 37. Code of Federo Tule 35. United States Citent or inventor's certiful I at least one country or ign application for pate I before that of the earlie	al Regulations, Social Regulations, Social Regulations, 119 and 119 an	Tection 1.56. P (a)-(d) or Section 365(a) of any PCT inited States, listed certificate, or PCT from which priority y Claimed

Filing Date 15. United States		Status
Of Their of Street		
Of Drived States		
Of Hained Stane		
loses and claims ser provided by the odisclose to the Ual to patentability ilable between the	subject matter in ad first paragraph of United States Patent y as defined in Titl filing date(s) of su	ldition to that disclose Title 35. United State t and Trademark Offic le 37. Code of Federa
8	loses and claims in provided by the provided by the provided by the last to the last to patentability lable between the provided and this applications.	Tiniernational Application(s) design loses and claims subject matter in adding subject matter in adding provided by the first paragraph of a disclose to the United States Patental to patentability as defined in Titulable between the filing date(s) of subject of this application:

And I hereby appoint

John P. White (Reg. No. 28,678); Christopher C. Dunham (Reg. No. 22,031); Norman H. Zivin (Reg. No. 25,385); Jay H. Maioli (Reg. No. 27,213); William E. Pelton (Reg. No. 25,702); Robert D. Katz (Reg. No. 30,141); Peter J. Phillips (Reg. No. 29,691); Wendy E. Miller (Reg. No. 35,615); Richard S. Milner (Reg. No. 33,970); Robert T. Maldonado (Reg. 38,232); Paul Teng (40,837); Richard F. Jaworski (Reg. No. 33,515); Elizabeth M. Wieckowski (Reg. No. 42,226); Pedro C. Fernandez (Reg. No. 41,741); Gary J. Gershik (Reg. No. 39,992); Jane M. Love (Reg. No. 42,812); Spencer H. Schneider (Reg. No. 45,923) and Raymond A. Diperna (Reg. No. 44,063).

and each of them, all c/o Cooper & Dunham LLP. 1185 Avenue of the Americas, New York, New York 10036, my attorneys, each with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to receive the patent, to transact all business in the Patent and Trademark Office connected therewith and to file any International Applications which are based thereon under the provisions of the Patent Cooperation Treaty.

Please address all communications, and direct all telephone call, regarding this application to:

John P. White, Esq.	Reg. No.	28,678
Cooper & Dunham LLP		
1185 Avenue of the Americas		
New York, New York 10036		
Tel. (212) 278-0400		

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole of first joint inventor	or Neil T. Parkin	
•	е	
-		Date of signature
		California 94002, U.S.A.
Full name of sole of first joint inventor _	r Rainer A. Ziermann	
Inventor's signature	·	
Citizenship	U.S.A.	Date of signature
Residence 3908	Leona Street, San Mateo	, California 94403, U.S.A.
Post Office Address	same as above	
Full name of sole or	-	
•		
_		Date of signature
Post Office Address		